Galderma Data Shows Sculptra and Restylane Efficacy in Menopause and Weight-Loss Aesthetic Changes
Event summary
- Interim data from two investigator-initiated trials (IITs) show Galderma's Sculptra and Restylane can address aesthetic changes linked to menopause and weight-loss medications.
- A nine-month study on menopausal women found that combining Restylane Skinboosters with Sculptra improved skin hydration and quality, with the best results when using Skinboosters first.
- Another trial revealed a four-fold reduction in adipose-derived stem cells (ADSCs) in patients taking weight-loss medications, suggesting why regenerative treatments like Sculptra are effective.
The big picture
Galderma's findings highlight the growing intersection of dermatology and systemic health changes, such as those caused by menopause or weight-loss medications. The company is positioning itself as a leader in regenerative aesthetics, leveraging its broad portfolio to address unmet needs in aging and metabolic health. This aligns with broader industry trends toward personalized, science-backed solutions in dermatology.
What we're watching
- Treatment Optimization
- How Galderma will refine treatment protocols for menopausal patients based on these findings.
- Market Expansion
- Whether the data will drive demand for Sculptra and Restylane in weight-loss aesthetic markets.
- Regulatory Strategy
- The pace at which Galderma advances regulatory approvals for expanded indications based on these trial results.
Related topics